High incidence of fosfomycin-resistant uropathogenic E. coli among children.
Escherichia coli
Fosfomycin resistance
Phylogenetic analysis
Urinary tract infections
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
17 Jul 2023
17 Jul 2023
Historique:
received:
17
03
2023
accepted:
08
07
2023
medline:
19
7
2023
pubmed:
18
7
2023
entrez:
17
7
2023
Statut:
epublish
Résumé
There are few epidemiological or molecular data on Escherichia coli (E. coli) strains resistant to fosfomycin. In this study, we described the occurrence and characterization of fosfomycin-resistant uropathogenic E. coli (UPEC) isolated from children. This study was carried out on 96 E. coli isolates obtained from children with urinary tract infections. Two methods were performed to detect fosfomycin resistance: The agar dilution method and the rapid fosfomycin test. The disc diffusion method was done to detect the antimicrobial susceptibility pattern of all isolates. The phylogenetic grouping of all isolates was done according to the modified Clermont method. Conventional PCR was performed to detect plasmid-mediated fosfomycin-resistant genes (fos genes) and the bla Analyses of data were performed by SPSS software. A high percentage of fosfomycin resistance (37/96; 38.5%) was reported among UPEC isolates. The fosfomycin-resistant strains showed a higher resistance rate than fosfomycin-susceptible isolates to different antibiotics. E group (62.2%) was the most predominant phylogenetic group among the fosfomycin-resistant UPEC isolates, followed by Group B2 (21.6%) and group D (13.5%). The fos genes were detected in 21 isolates with the fosA3 gene as the most frequent, which was detected in 11 isolates followed by fosA (8), fosC2 (4), fosA4(1), and fosA5(1) genes. This is the first report of a high prevalence of plasmid-mediated fosfomycin-resistant UPEC in Egypt. All of these isolates were multidrug-resistant to the tested antibiotics. Close monitoring of such strains is mandatory to prevent widespread dissemination of the genes code for antibiotic resistance.
Sections du résumé
BACKGROUND
BACKGROUND
There are few epidemiological or molecular data on Escherichia coli (E. coli) strains resistant to fosfomycin. In this study, we described the occurrence and characterization of fosfomycin-resistant uropathogenic E. coli (UPEC) isolated from children.
MATERIALS AND METHODS
METHODS
This study was carried out on 96 E. coli isolates obtained from children with urinary tract infections. Two methods were performed to detect fosfomycin resistance: The agar dilution method and the rapid fosfomycin test. The disc diffusion method was done to detect the antimicrobial susceptibility pattern of all isolates. The phylogenetic grouping of all isolates was done according to the modified Clermont method. Conventional PCR was performed to detect plasmid-mediated fosfomycin-resistant genes (fos genes) and the bla
RESULTS
RESULTS
Analyses of data were performed by SPSS software. A high percentage of fosfomycin resistance (37/96; 38.5%) was reported among UPEC isolates. The fosfomycin-resistant strains showed a higher resistance rate than fosfomycin-susceptible isolates to different antibiotics. E group (62.2%) was the most predominant phylogenetic group among the fosfomycin-resistant UPEC isolates, followed by Group B2 (21.6%) and group D (13.5%). The fos genes were detected in 21 isolates with the fosA3 gene as the most frequent, which was detected in 11 isolates followed by fosA (8), fosC2 (4), fosA4(1), and fosA5(1) genes.
CONCLUSION
CONCLUSIONS
This is the first report of a high prevalence of plasmid-mediated fosfomycin-resistant UPEC in Egypt. All of these isolates were multidrug-resistant to the tested antibiotics. Close monitoring of such strains is mandatory to prevent widespread dissemination of the genes code for antibiotic resistance.
Identifiants
pubmed: 37460976
doi: 10.1186/s12879-023-08449-9
pii: 10.1186/s12879-023-08449-9
pmc: PMC10353200
doi:
Substances chimiques
Fosfomycin
2N81MY12TE
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
475Informations de copyright
© 2023. The Author(s).
Références
Microb Drug Resist. 2013 Dec;19(6):477-82
pubmed: 23909549
J Infect Public Health. 2020 Oct;13(10):1537-1543
pubmed: 32690453
J Clin Microbiol. 2019 Jan 2;57(1):
pubmed: 30381418
Lett Appl Microbiol. 2022 Mar;74(3):334-343
pubmed: 34839528
Antimicrob Agents Chemother. 2010 Jul;54(7):3061-4
pubmed: 20404116
Rev Argent Microbiol. 2022 Apr-Jun;54(2):120-124
pubmed: 34154873
Antibiotics (Basel). 2021 Jul 09;10(7):
pubmed: 34356756
Clin Infect Dis. 2011 Mar 1;52(5):e103-20
pubmed: 21292654
J Antimicrob Chemother. 2009 Oct;64(4):712-7
pubmed: 19671590
Enferm Infecc Microbiol Clin (Engl Ed). 2018 Aug - Sep;36(7):417-422
pubmed: 28993064
J Glob Antimicrob Resist. 2020 Jun;21:414-416
pubmed: 32061811
Rev Esp Quimioter. 2019 May;32 Suppl 1:55-61
pubmed: 31131593
Arab J Gastroenterol. 2019 Jun;20(2):74-80
pubmed: 30905635
JAMA Pediatr. 2016 Sep 1;170(9):848-54
pubmed: 27455161
Braz J Microbiol. 2014 Aug 29;45(2):509-14
pubmed: 25242935
J Clin Med. 2023 Mar 21;12(6):
pubmed: 36983414
Environ Microbiol. 2021 Nov;23(11):7139-7151
pubmed: 34431197
Environ Microbiol Rep. 2013 Feb;5(1):58-65
pubmed: 23757131
Transl Pediatr. 2022 Jun;11(6):859-868
pubmed: 35800289
Antimicrob Agents Chemother. 2012 Apr;56(4):2135-8
pubmed: 22232290
Clin Microbiol Rev. 2016 Apr;29(2):321-47
pubmed: 26960938
BMC Infect Dis. 2020 Feb 7;20(1):108
pubmed: 32033541
Sci Rep. 2020 Feb 17;10(1):2772
pubmed: 32066805
Rev Soc Bras Med Trop. 2020 Feb 07;53:e20190429
pubmed: 32049204
J Antimicrob Chemother. 1997 Sep;40(3):393-9
pubmed: 9338493
Appl Microbiol Biotechnol. 2022 Feb;106(3):1279-1298
pubmed: 35050388
Emerg Infect Dis. 2017 Sep;23(9):1564-1567
pubmed: 28820368
Antibiotics (Basel). 2020 Aug 24;9(9):
pubmed: 32847131
PLoS One. 2015 Aug 07;10(8):e0135269
pubmed: 26252888
FEMS Microbiol Lett. 2002 Apr 9;209(2):161-8
pubmed: 12007800
Epidemiol Infect. 2017 Mar;145(4):818-824
pubmed: 27938421
S Afr J Infect Dis. 2022 Jan 19;37(1):321
pubmed: 35169586
Eur J Clin Microbiol Infect Dis. 2019 May;38(5):945-949
pubmed: 30877486
Rev Esp Quimioter. 2019 May;32 Suppl 1:8-18
pubmed: 31131587